Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Non-Current Assets (2023 - 2025)

Compass Therapeutics' Non-Current Assets history spans 3 years, with the latest figure at $9.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 27.67% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $37.7 million, up 86.17%, while the annual FY2025 figure was $9.8 million, 27.67% up from the prior year.
  • Non-Current Assets for Q4 2025 was $9.8 million at Compass Therapeutics, down from $10.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $10.5 million in Q2 2025 and bottomed at $2.1 million in Q2 2024.
  • The 3-year median for Non-Current Assets is $5.8 million (2023), against an average of $6.1 million.
  • The largest annual shift saw Non-Current Assets crashed 47.17% in 2024 before it soared 408.62% in 2025.
  • A 3-year view of Non-Current Assets shows it stood at $3.0 million in 2023, then skyrocketed by 155.58% to $7.7 million in 2024, then increased by 27.67% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Non-Current Assets are $9.8 million (Q4 2025), $10.1 million (Q3 2025), and $10.5 million (Q2 2025).